News for Resverlogix Corp. (RVX.TO)

/PRNewswire/ -- DelveInsight's Atherosclerotic Cardiovascular Disease Market Insights report includes a comprehensive understanding of current treatment...

Condensed Interim Consolidated Financial Statements For the three and six months ended June 30, 2023 and 2022 ... -Today at 02:23 am- MarketScreener

/PRNewswire/ -- The "Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By...

Source: Clive Maund April 6, 2023 (Investorideas.com Newswire) In light of its recent development of a product that purportedly has the ability to reset damage...

Annual Information Form Fiscal Year Ended December 31, 2021 March 31, 2022 Change in Fiscal Year-End ... | March 31, 2023

Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2022 and 2021 Notice of No... | November 12, 2022

Read Resverlogix (TSE:RVX) Stock Price Down 11.4% at ETF Daily News

CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announced that apabetalone’s future…

CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the appointment of Dr. Ewelina Kulikowski,…

Read Resverlogix (TSE:RVX) Stock Passes Below Fifty Day Moving Average of $0.26 at ETF Daily News

CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that it has closed a…

National Cancer Institute Sponsored Phase 1/1b clinical study to test combination of epigenetic and immune-oncology therapies in solid tumors and ovarian cancer

Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment GlobeNewswire November 15, 2021 CALGARY, Alberta, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics”), a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara Biopharma Co.,...

ZEN-3694 has therapeutic potential in combination with CDK4/6 inhibitors in patients with advanced ER+ breast cancer resistant to CDK4/6 inhibitors...

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announces that on May 13, 2021, it acquired 10% secured convertible debentures due May 13, 2022, of Resverlogix Corp. in the principal amount of... | May 21, 2021

CALGARY, Alberta, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or the "Company") (TSX:RVX) announces that it has postponed ...